WARREN, N.J., Jan. 3, 2019 /PRNewswire/ -- Aquestive
Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical
company focused on identifying, developing and commercializing
differentiated products to solve therapeutic problems, today
announced the appointment of Gary H.
Slatko as SVP, Chief Medical Officer (CMO). Dr. Slatko will
lead clinical and medical affairs for the company, and is reporting
to CEO Keith J. Kendall, effective
January 2, 2019.
"We are pleased to have Dr. Slatko join Aquestive and further
our work in improving medications and outcomes for patients," said
Keith J. Kendall, Chief Executive
Officer of Aquestive Therapeutics. "Dr. Slatko's experience at the
FDA and in the pharmaceutical industry will benefit Aquestive's
entire proprietary pipeline, including our late-stage development
programs, Libervant™ (diazepam) buccal film and Exservan™
(riluzole) oral film. Additionally, his depth of medical experience
will be beneficial to our commercial teams as we engage with
physicians and nurses to raise awareness of Sympazan, which
launched late last year."
Dr. Slatko's experience includes six years in drug safety
regulatory work at the U.S. Food and Drug Administration as a
director in the Office of Medication Error Prevention and Risk
Management. He also spent over a decade of time as the CMO of a
biopharmaceutical consulting firm, ParagonRx, a Syneos Health
(formerly InVentiv Health) company. Previously, he
held various drug safety, clinical program, new product
planning, medical affairs, and executive leadership roles over a
15-year pharmaceutical industry career at Squibb, DuPont Merck,
AstraZeneca, and GlaxoSmithKline.
Dr. Slatko received a B.A. from Emory
University, a M.D. from the University
of Miami School of Medicine, and a M.B.A. from West Chester University. He is Board certified in
Internal Medicine.
"I am truly excited to join Aquestive," said Dr. Slatko.
"Aquestive is at an important moment in its growth, and I look
forward to working alongside my new colleagues to help further
their goal of bringing differentiated treatments to patients."
About Aquestive Therapeutics
Aquestive Therapeutics is
a specialty pharmaceutical company focused on identifying,
developing and commercializing differentiated products to solve
therapeutic problems. Aquestive Therapeutics has a late-stage
proprietary product pipeline and a commercialized product,
Sympazan™ (clobazam), focused on the treatment of CNS
diseases, and is working to advance orally-administered complex
molecules that it believes can be alternatives to
invasively-administered standard of care therapies. As the leader
in developing and delivering drugs via its PharmFilm®
technology, Aquestive Therapeutics also collaborates with
pharmaceutical partners to bring new molecules to market in
differentiated and highly-marketable dosage forms.
Media inquiries:
Christopher Hippolyte
christopher.hippolyte@syneoshealth.com
212-364-0458
Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aquestive-therapeutics-appoints-gary-h-slatko-md-as-chief-medical-officer-300772782.html
SOURCE Aquestive Therapeutics, Inc.